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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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On Tuesday, September 22, when the U.S. Food and Drug Administration
(FDA) focuses on Huntington’s disease drug development at a meeting
with affected individuals and advocates, HD families must drive home the
sorrowful truth: people are dying because of the lack of effective
treatments.
About two weeks ago, shortly after pouring out my heart about my family’s
HD struggles on the FDA’s pre-meeting questionnaire, I received a
message from the mother of 18-year-old Terry Leach of San Diego: “It’s
Terry’s final days if you wanted to say good-bye.”
A couple days later, on Labor Day, I visited Terry, who suffers from
juvenile HD, in his bedroom. As Terry slept, his mother Angela and I
looked on. Next to us a home healthcare worker prepared a can of liquid
food to be administered via a feeding tube attached to Terry’s abdomen.
Hospice workers are also helping.
“He grew a lot,” I said to Angela, amazed at how, despite the particularly
cruel toll of juvenile HD, his body had strived to develop. It had been more
than a year since I had last seen Terry.
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“Yes, he did,” Angela said.
I noticed Terry’s beard and his healthy head of somewhat wiry, dark brown
hair.
“You have a very handsome son,” I continued.
“Thank you,” Angela said.
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Terry Leach resting at home (family photo)
Unspeakable pain
As Angela nervously shifted her balance from foot to foot, I sensed that she
continued to carry the unspeakable burden that comes with juvenile HD:
Terry’s first symptoms as an infant, his need for a full-time aide in school
after losing his ability to walk and talk, the insertion of the feeding tube in
2010, Botox injections into his arms and legs in recent years to relieve
pain, and leg and foot operations, among other procedures and
hospitalizations.
Although Terry still attended school last academic year and also the
summer session, he has declined considerably in the last few months,
Angela said.
The night before my visit, he vomited after receiving liquid food through
his tube. On the day I visited, the aide would give him only one can instead
of the usual two, noting that his body would not accept anything more than
that very small amount.
I asked Angela if I could touch Terry.
“Sure,” she said softly.
I ran my hand along the top of his hair. I remembered Angela and her
family’s steadfastness in caring for Terry. I also recalled fondly our
collaboration in the cause, starting with an article I wrote about them in
2009. In 2012, Terry emerged as “SuperTerry” in an artist’s comic-book
like rendition as a hero defeating HD. In 2014, our families participated in
the 2014 Team Hope Walk of the San Diego Chapter of the Huntington’s
Disease Society of America.
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SuperTerry in San Diego artist Lee Ellingson's rendition (above) and
with Gene Veritas (aka Kenneth P. Serbin) at the 2014 Team Hope Walk
(below, photo by Misty Oto)

Seeking feedback from the community
As Terry lies dying, the September 22 FDA event, a public meeting on
“patient-focused drug development,” will seek feedback from affected
individuals and others in the HD community.
The meeting will occur from 9 a.m.-12:30 p.m. at the FDA’s White Oak
Campus in Silver Spring, MD. Pre-registration for attending the meeting
and viewing via webcast is closed, but the FDA will make available a video
of the proceedings shortly thereafter.
The meeting stems from the reauthorization of the Prescription Drug User
Fee Act in 2012, in which Congress required the FDA to more
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systematically solicit input from patient communities with regard to drug
development. The FDA hopes this will help its review process.
Huntington’s disease became one of just 20 diseases selected by the FDA
for a patient-focused meeting through the end of 2015.
‘Nothing for neurological disorders’
Responding to the preparatory questionnaire, I revealed my situation as a
carrier of the HD genetic defect and my mother’s decline and death from
HD in 2006.
“I fear that I will become like my mother,” I wrote. “She had mild chorea
[involuntary movements associated with HD]. I would not mind having
chorea as long as I can continue to be myself, work, and not become a
burden on my wife and daughter. My mother became a shadow of herself. I
have great anxiety about losing my personality and ability to work as a
college professor and writer.”
Like others, I would like to see a treatment that prevented symptoms, I
added.
“If I get symptoms, then I would like a medication that allows me to
manage the disease just as other diseases such as diabetes are managed
without affecting a person’s livelihood, family life, or activities in general,”
I continued. “There are lots of advances in cancer treatments, for instance,
but really nothing in the field of neurological disorders that prevents, halts,
or reverses the condition.”
I uploaded my response to the FDA’s public docket regarding the meeting.
Anybody can comment at that link through November 23, 2015.
Speeding up clinical trials
At the meeting, I also plan to urge FDA officials to allow researchers and
clinical trial administrators to use new technologies to measure the effect
of medicines.
All clinical trials of new drugs taking place in the U.S. must receive the
approval of the FDA, considered to have the world’s most rigorous
standards. Although the drug industry executives I have met recognize the
importance of that rigor in assuring the manufacture of safe and effective
drugs, they sometimes have also expressed the need for the FDA to be
more flexible and allow for faster clinical trials.
Generally, the FDA still does not accept techniques such as brain scans.
HD researchers and other scientists are vigorously searching for
biomarkers – signs of disease and drug effectiveness – in the blood,
cerebrospinal fluid, and other materials taken from the body that can be
measured using the scans and other new techniques.
Instead of waiting for a doctor’s clinical observation of an improvement,
these techniques could potentially allow faster and earlier reading of a
drug’s effectiveness.
I will stress that the FDA work closely with scientists and the HD
community to make clinical trials as efficient and meaningful as possible.
Speed is of the essence for the HD community.
Heartbroken by another loss
As of this writing, Terry is stable, but his prognosis is not positive.
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To give me strength as I travel to Maryland on September 21 and take part
in the meeting the next day, I will keep fresh my memory of Terry.
I am heartbroken by yet another loss to HD.
As an advocate, I feel I have failed to fulfill the promise of hope presented
so often to families such as the Leaches. No 18-year-old should die.
I am comforted to know that Terry is in loving hands – and that he never
gave up, always smiling that infectious smile. And I am committed to
making sure policymakers know of the people whose lives they could
improve and save.

Terry in 2010 as a Hero of the Carlsbad Marathon
Posted by Gene Veritas at 6:45 AM
Labels: advocates , brain scan , clinical trials , drug development , FDA , feeding
tube , Huntington's disease , patients , researcher , scientists , symptoms , Terry
Leach

2 comments:
Charles said...
YEAH! Terry! Keep Up The GOOD Fight!
Chop-n-Moe
8:13 PM, September 18, 2015

jakby said...
Hi, have you maybe tried Triheptanoin? it is synthetic oil
described here: http://en.hdbuzz.net/185 I wonder how to get
it.
10:35 AM, September 19, 2015

Post a Comment

Newer Post

Home

Older Post

Subscribe to: Post Comments (Atom)

curehd.blogspot.com/2015/09/as-he-lay-dying-fda-and-huntingtons.html

5/6

11/18/21, 12:14 PM

At Risk for Huntington's Disease: As he lay dying: FDA and Huntington’s disease families meet to ponder potential treatments

curehd.blogspot.com/2015/09/as-he-lay-dying-fda-and-huntingtons.html

6/6

